GlassScriptPhysician profile
William J Andrew
NPI 1760488761
$6,610.99
in general payments reported to CMS, 2019-2025
35 companies · $902 in 2025
The $902 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $218 · 2021: $652 · 2022: $1,584 · 2023: $1,546 · 2024: $1,147 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,357 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.01 |
| Education | $237.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $952.37 | 2019-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $784.81 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $777.28 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $736.80 | 2023-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $418.96 | 2022-2023 | Ova1 |
| Coopersurgical, INC. | $330.72 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Exeltis, USA INC. | $228.08 | 2019-2025 | Slynd |
| Merck Sharp & Dohme LLC | $196.68 | 2019-2025 | Gardasil 9, Gardasil |
| Mayne Pharma Commercial LLC | $195.57 | 2022-2025 | |
| Organon LLC | $181.03 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $179.42 | 2019-2022 | |
| Novo Nordisk INC | $156.28 | 2019-2025 | Wegovy |
| Hologic Sales and Service, LLC | $141.75 | 2019-2024 | Fluent Fluid Management System, Acessa Provu System |
| Sage Therapeutics, LLC | $130.69 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $122.94 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $121.87 | 2019-2025 | |
| Shield Therapeutics INC | $111.60 | 2023-2024 | Accrufer |
| Channel Medsystems, INC. | $110.58 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $96.43 | 2021-2024 | Contrave |
| Exact Sciences Corporation | $95.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Agile Therapeutics, INC. | $87.77 | 2022-2023 | Twirla |
| Baxter Healthcare | $66.27 | 2019-2025 | Perclot |
| Millicent US INC | $58.10 | 2025 | Femlyv, Intrarosa |
| Evofem Biosciences, INC. | $56.18 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $55.60 | 2021-2022 | |
| Lupin INC. | $40.60 | 2020-2021 | |
| Amgen INC. | $32.87 | 2019-2021 | |
| Sanara Medtech INC. | $30.47 | 2021 | |
| Ge Healthcare | $20.53 | 2023 | |
| Medtronic Minimed, INC. | $18.18 | 2019 | |
| Allergan, INC. | $17.67 | 2020 | |
| Smith+Nephew, INC. | $17.38 | 2019 | |
| Lilly USA, LLC | $13.52 | 2024 | Zepbound |
| Si-Bone, INC. | $13.25 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Andrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.